EVALUATION OF THE EFFECTIVENESS OF THE ADDITIONAL RISK MINIMISATION MEASURES FOR GLOFITAMAB: A PASS SURVEY AMONG HEALTHCARE PROFESSIONALS IN EUROPEAN COUNTRIES

ENCePP Code of conduct

Yes

Data sources

• Data source(s), other:
  OneKeyTM database
• Data sources (types):
  Patient surveys

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No